They’ve come a long way in 12 months. Here’s an up-to-date snapshot of where they are now.
A bitter Congressional fight over the cost of superexpensive biotechnology drugs has come down to a single, hotly debated number: How many years should makers of those drugs be exempt from generic competition?
A late rally pushed stocks higher Tuesday following better-than-expected earnings from several Dow components. The Dow logged its seventh-straight gain, the Nasdaq, it's tenth.
The Mad Money host makes the call on a few key blue-chip companies and more.
The Dow advanced Tuesday as a slew of components beat earnings expectations. But there were pockets of weakness throughout the market, including chips, hardware, banks and retail. The Nasdaq was lower.
Recently, Merck came out with the first vaccine for shingles called Zostavax. But it had manufacturing and supply issues that hurt the launch. In its earnings press release today, Merck says as of last month it has "resumed normal shipping schedules for Zostavax."
U.S. drugmaker Schering-Plough said on Tuesday its second-quarter earnings rose after lower special charges, but global revenue declined as the weak dollar hurt sales in overseas markets.
The Dow bolted out of the gate Tuesday as a slew of components beat earnings expectations. But there were pockets of weakness throughout the market, including chips, hardware, banks and retail. The Nasdaq was lower.
Futures indicated a slightly lower open for Wall Street Tuesday ahead of a slew of earnings and Federal Reserve Chairman Ben Bernanke's Capitol Hill testimony.
Stocks rallied to the finish line Monday after a wobbly morning as a CIT deal to avert bankruptcy and strong earnings gave investors cause for optimism.
A strong start for stocks began to peter out Monday, though CIT continued to rally.
Stocks opened higher Monday as investors were cheered by news of a deal that will avoid bankruptcy for commercial lender CIT Group and a better-than-expected start the earnings season.
Futures indicated a positive open for Wall Street Monday as investors were cheered by news of a deal that will avoid bankruptcy for commercial lender CIT Group.
The Food and Drug Administration today announced that Teva Pharmaceutical Industries is voluntarily recalling two lots of the anesthetic Propofol because there are higher levels of potentially fatal endotoxins...Propofol is the same drug that was reportedly found in Michael Jackson’s house.
Carl Icahn and all of the Elanians should be happy. Biogen Idec today reported encouraging trends regarding its all-important multiple sclerosis drug Tysabri.
Two congressmen who are tackling the new healthcare legislation don't want to go too far in implementing potential solutions, however.
Man, time flies. I can't believe almost a year has passed since the incident at ICAD. That's the big Alzheimer's Disease scientific research conference that was held in Chicago in late July last year. This year, it's in Vienna and it's going on right now.
A full-blown swine flu pandemic hitting the UK could see one in four employees forced to stay home at a cost of 1.5 billion pounds ($2.4 billion) each day, new research suggests.
For years now, but especially in recent months, I've been covering the obesity epidemic. I regularly report on the statistics and the experimental drug data, detached and "objective" as I think any good reporter should be. It just didn't occur to me that the target population might include my sister.
I was wrong. I'd blogged a few times that I thought the FDA might have a problem with "Effient," Eli Lilly's proposed name for its bloodthinner, because it was too close to efficient and all the connotations that would have.